Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 278

1.

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.

Pignone M, Earnshaw S, Tice JA, Pletcher MJ.

Ann Intern Med. 2006 Mar 7;144(5):326-36.

PMID:
16520473
2.

Summaries for patients. The cost-effectiveness of aspirin, statins, or both drugs in the primary prevention of heart disease.

[No authors listed]

Ann Intern Med. 2006 Mar 7;144(5):I29. No abstract available.

PMID:
16520469
3.

Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis.

Pignone M, Earnshaw S, Pletcher MJ, Tice JA.

Arch Intern Med. 2007 Feb 12;167(3):290-5.

PMID:
17296886
4.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

7.

Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.

Greving JP, Visseren FL, de Wit GA, Algra A.

BMJ. 2011 Mar 30;342:d1672. doi: 10.1136/bmj.d1672.

PMID:
21450800
8.

Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.

Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC.

Ann Intern Med. 2000 May 16;132(10):769-79.

PMID:
10819699
9.

Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.

Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, Lightwood J, Williams L, Goldman L.

Ann Intern Med. 2009 Feb 17;150(4):243-54.

PMID:
19221376
10.
11.

Cost-utility of aspirin and proton pump inhibitors for primary prevention.

Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M.

Arch Intern Med. 2011 Feb 14;171(3):218-25. doi: 10.1001/archinternmed.2010.525.

12.

Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.

Fidan D, Unal B, Critchley J, Capewell S.

QJM. 2007 May;100(5):277-89. Epub 2007 Apr 21.

PMID:
17449875
14.

Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.

Kourlaba G, Fragoulakis V, Maniadakis N.

Appl Health Econ Health Policy. 2012 Jul 1;10(4):261-71. doi: 10.2165/11633820-000000000-00000.

PMID:
22667992
15.

Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.

Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG, Goldman L.

N Engl J Med. 2002 Jun 6;346(23):1800-6.

16.

Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.

Greving JP, Buskens E, Koffijberg H, Algra A.

Circulation. 2008 Jun 3;117(22):2875-83. doi: 10.1161/CIRCULATIONAHA.107.735340. Epub 2008 May 27.

17.

Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction.

Ganz DA, Kuntz KM, Jacobson GA, Avorn J.

Ann Intern Med. 2000 May 16;132(10):780-7. Erratum in: Ann Intern Med 2002 Apr 16;136(8):635.

PMID:
10819700
18.
19.

Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.

Chan PS, Nallamothu BK, Gurm HS, Hayward RA, Vijan S.

Circulation. 2007 May 8;115(18):2398-409. Epub 2007 Apr 23.

20.

A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.

Tsutani K, Igarashi A, Fujikawa K, Evers T, Kubin M, Lamotte M, Annemans L.

Intern Med. 2007;46(4):157-62. Epub 2007 Feb 15.

Supplemental Content

Support Center